Barriers to Liposomal Gene Delivery: from Application Site to the Target

Overview

Journal Iran J Pharm Res

Publisher Brieflands

Specialty Pharmacology

Date 2017 Feb 24

PMID 28228799

Citations 24

Authors

Mostafa Saffari

Hamid Reza Moghimi

Crispin R Dass

Affiliations

Soon will be listed here.

Abstract

Gene therapy is a therapeutic approach to deliver genetic material into cells to alter their function in entire organism. One promising form of gene delivery system (DDS) is liposomes. The success of liposome-mediated gene delivery is a multifactorial issue and well-designed liposomal systems might lead to optimized gene transfection particularly in vivo. Liposomal gene delivery systems face different barriers from their site of application to their target, which is inside the cells. These barriers include presystemic obstacles (epithelial barriers), systemic barriers in blood circulation and cellular barriers. Epithelial barriers differ depending on the route of administration. Systemic barriers include enzymatic degradation, binding and opsonisation. Both of these barriers can act as limiting hurdles that genetic material and their vector should overcome before reaching the cells. Finally liposomes should overcome cellular barriers that include cell entrance, endosomal escape and nuclear uptake. These barriers and their impact on liposomal gene delivery will be discussed in this review.

Citing Articles

The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases.

Okafor N, Omoteso O, Choonara Y Discov Nano. 2025; 20(1):19.

PMID: 39883380 PMC: 11782757. DOI: 10.1186/s11671-024-04170-x.

Plasmid Gene Therapy for Monogenic Disorders: Challenges and Perspectives.

Luis M, Goes M, Santos F, Mesquita J, Tavares-Ratado P, Tomaz C Pharmaceutics. 2025; 17(1).

PMID: 39861752 PMC: 11768343. DOI: 10.3390/pharmaceutics17010104.

Non-Viral Delivery Systems to Transport Nucleic Acids for Inherited Retinal Disorders.

Jony M, Joshi A, Dash A, Shukla S Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861150 PMC: 11768406. DOI: 10.3390/ph18010087.

Exploring the potential of nanomedicine for gene therapy across the physicochemical and cellular barriers.

Hameed H, Sarwar H, Younas K, Zaman M, Jamshaid M, Irfan A Funct Integr Genomics. 2024; 24(5):177.

PMID: 39340586 DOI: 10.1007/s10142-024-01459-z.

Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders.

Lasheen N, Allam S, Elgarawany A, Aswa D, Mansour R, Farouk Z J Physiol Sci. 2024; 74(1):46.

PMID: 39313800 PMC: 11421184. DOI: 10.1186/s12576-024-00933-4.

References

Dass C, Saravolac E, Li Y, Sun L . Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev. 2002; 12(5):289-99. DOI: 10.1089/108729002761381276. View

Hangai M, Kaneda Y, Tanihara H, Honda Y . In vivo gene transfer into the retina mediated by a novel liposome system. Invest Ophthalmol Vis Sci. 1996; 37(13):2678-85. View

Rosenecker J, Naundorf S, Gersting S, Hauck R, Gessner A, Nicklaus P . Interaction of bronchoalveolar lavage fluid with polyplexes and lipoplexes: analysing the role of proteins and glycoproteins. J Gene Med. 2003; 5(1):49-60. DOI: 10.1002/jgm.291. View

Merdan T, Kopecek J, Kissel T . Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev. 2002; 54(5):715-58. DOI: 10.1016/s0169-409x(02)00046-7. View

Lee J, Yokota T . Antisense therapy in neurology. J Pers Med. 2015; 3(3):144-76. PMC: 4251390. DOI: 10.3390/jpm3030144. View

Dass C . Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J Mol Med (Berl). 2004; 82(9):579-91. DOI: 10.1007/s00109-004-0558-8. View

Chan C, Jans D . Enhancement of MSH receptor- and GAL4-mediated gene transfer by switching the nuclear import pathway. Gene Ther. 2001; 8(2):166-71. DOI: 10.1038/sj.gt.3301366. View

Bitko V, Barik S . Nasal delivery of siRNA. Methods Mol Biol. 2008; 442:75-82. DOI: 10.1007/978-1-59745-191-8_6. View

Dass C . Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature. Int J Pharm. 2003; 267(1-2):1-12. DOI: 10.1016/j.ijpharm.2003.08.010. View

10.

Hatayama M, Tomizawa T, Sakai-Kato K, Bouvagnet P, Kose S, Imamoto N . Functional and structural basis of the nuclear localization signal in the ZIC3 zinc finger domain. Hum Mol Genet. 2008; 17(22):3459-73. PMC: 2572694. DOI: 10.1093/hmg/ddn239. View

11.

Channarong S, Chaicumpa W, Sinchaipanid N, Mitrevej A . Development and evaluation of chitosan-coated liposomes for oral DNA vaccine: the improvement of Peyer's patch targeting using a polyplex-loaded liposomes. AAPS PharmSciTech. 2011; 12(1):192-200. PMC: 3066342. DOI: 10.1208/s12249-010-9559-9. View

12.

Tezel A, Dokka S, Kelly S, Hardee G, Mitragotri S . Topical delivery of anti-sense oligonucleotides using low-frequency sonophoresis. Pharm Res. 2005; 21(12):2219-25. DOI: 10.1007/s11095-004-7674-6. View

13.

Martin T, Wysocki B, Beyersdorf J, Wysocki T, Pannier A . Integrating mitosis, toxicity, and transgene expression in a telecommunications packet-switched network model of lipoplex-mediated gene delivery. Biotechnol Bioeng. 2014; 111(8):1659-71. DOI: 10.1002/bit.25207. View

14.

Rothdiener M, Muller D, Castro P, Scholz A, Schwemmlein M, Fey G . Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Release. 2010; 144(2):251-8. DOI: 10.1016/j.jconrel.2010.02.020. View

15.

Nicol C, Denby L, Lopez-Franco O, Masson R, Halliday C, Nicklin S . Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature. FEBS Lett. 2009; 583(12):2100-7. DOI: 10.1016/j.febslet.2009.05.037. View

16.

Semple S, Klimuk S, Harasym T, Hope M . Lipid-based formulations of antisense oligonucleotides for systemic delivery applications. Methods Enzymol. 1999; 313:322-41. DOI: 10.1016/s0076-6879(00)13020-4. View

17.

Dass C, Burton M . A model for evaluating selective delivery of plasmid DNA to tumours via the vasculature. Cancer Biother Radiopharm. 2002; 17(5):501-5. DOI: 10.1089/108497802760804727. View

18.

Tan M, Choong P, Dass C . Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides. 2009; 31(1):184-93. DOI: 10.1016/j.peptides.2009.10.002. View

19.

Kluza E, van der Schaft D, Hautvast P, Mulder W, Mayo K, Griffioen A . Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 2009; 10(1):52-8. DOI: 10.1021/nl902659g. View

20.

Jiang H, Kim Y, Arote R, Jere D, Quan J, Yu J . Mannosylated chitosan-graft-polyethylenimine as a gene carrier for Raw 264.7 cell targeting. Int J Pharm. 2009; 375(1-2):133-9. DOI: 10.1016/j.ijpharm.2009.03.033. View